Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | PYGL | P06737 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29092627 | 0.89 | POLB (0.50) | POLBHRH3MAPTHTTNPC1 | |
| SCHEMBL5390617 | 0.88 | CYP4A11 (0.51) | CYP4F2CYP4A11POLBNPC1HPGD | |
| SCHEMBL14052828 | 0.85 | HRH3 (0.61) | CYP4F2CYP4A11CA2HRH3MAPT | |
| SCHEMBL5619 | 0.83 | POLB (0.46) | POLBHRH3MAPTHTTNPC1 | |
| SCHEMBL1276799 | 0.83 | MEN1 (0.47) | POLBPYGLNPC1HPGDRAB9A | |
| SCHEMBL8868654 | 0.82 | EPHX1 (0.63) | TDP1HRH3MAPTHTTNPC1 | |
| SCHEMBL19668154 | 0.82 | HTR6 (0.49) | TDP1POLBHRH3SMN1; SMN2 | |
| SCHEMBL7123533 | 0.82 | CYP4F2 (0.47) | CYP4F2CYP4A11TDP1CA2POLB | |
| SCHEMBL2022898 | 0.82 | POLB (0.57) | CA2POLBMAPTNPC1HPGD | |
| SCHEMBL6629816 | 0.82 | SMN1; SMN2 (0.57) | CYP4F2CYP4A11TDP1CA2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4333899-A1 | COMPOUNDS FOR TARGETING DEGRADATION OF BRUTON'S TYROSINE KINASE | Biogen MA Inc. (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-4334290-A1 | CHELATORS FOR RADIOMETALS AND METHODS OF MAKING AND USING SAME | The University of British Columbia (CA) | 2024-03-13 | — | — | EP | disclosed |
| WO-2022232943-A1 | CHELATORS FOR RADIOMETALS AND METHODS OF MAKING AND USING SAME | THE UNIVERSITY OF BRITISH COLUMBIA (CA) | 2022-11-10 | — | — | WO | disclosed |
| EP-3820474-A1 | ADENOSINE RECEPTOR BINDING COMPOUNDS | Nikang Therapeutics, Inc. (US) | 2021-05-19 | — | — | EP | disclosed |
| EP-2870156-B1 | PYRIMIDINONE DERIVATIVES AS ANTIMALARIAL AGENTS | SANOFI SA (FR) | 2020-06-17 | — | — | EP | disclosed |
| EP-2994470-B1 | PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | PRINCIPIA BIOPHARMA INC (US) | 2018-04-18 | — | — | EP | disclosed |
| US-9630963-B2 | Quinolone derivatives as fibroblast growth factor inhibitors | PRINCIPIA BIOPHARMA, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| CN-104583212-B | pyrimidinone derivatives as antimalarial agents | 赛诺菲 | 2017-04-19 | — | — | CN | disclosed |
| EP-3134125-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | Pierre Fabre Médicament (FR) | 2017-03-01 | — | — | EP | disclosed |
| EP-2493862-B1 | IMIDAZOLE DERIVATIVES AS IDO INHIBITORS | NEWLINK GENETICS CORP (US) | 2016-10-05 | — | — | EP | disclosed |
| EP-2994470-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | Principia Biopharma Inc. (US) | 2016-03-16 | — | — | EP | disclosed |
| WO-2015162293-A1 | ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER | PIERRE FABRE MEDICAMENT (FR) | 2015-10-29 | — | — | WO | disclosed |
| US-20150183804-A1 | Pyrimidinone Derivatives as Antimalarial Agents | SANOFI (FR) | 2015-07-02 | — | — | US | disclosed |
| EP-2870156-A1 | PYRIMIDINONE DERIVATIVES AS ANTIMALARIAL AGENTS | SANOFI (FR) | 2015-05-13 | — | — | EP | disclosed |
| WO-2014182829-A1 | QUINOLONE DERIVATIVES AS FIBROBLAST GROWTH FACTOR INHIBITORS | PRINCIPIA BIOPHARMA INC. (US) | 2014-11-13 | — | — | WO | disclosed |
| US-8853258-B2 | C-linked hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-10-07 | — | — | US | disclosed |
| WO-2013190123-A1 | PYRIMIDINONE DERIVATIVES AS ANTIMALARIAL AGENTS | SANOFI (FR) | 2013-12-27 | — | — | WO | disclosed |
| EP-2488489-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | BROWN MATTHEW FRANK (US) | 2012-08-09 | — | — | US | disclosed |
| WO-2011045703-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | HAX1, LPXN, AGXT | CYP4F2 3646/4885CYP4A11 4699/4885TDP1 2637/4885 |
| US-20150183804-A1 | Pyrimidinone Derivatives as Antimalarial Agents | DHFR, PRMT1, PRMT7 | CYP4F2 728/4885CYP4A11 1998/4885TDP1 3113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.